Research programme: bispecific antibodies - Genmab/Janssen BiotechAlternative Names: EM1-mAb DuoBody
Latest Information Update: 21 Oct 2014
At a glance
- Originator Genmab; Janssen Biotech
- Developer Genmab
- Class Bispecific antibodies
- Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Proto oncogene protein c met modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer